207 related articles for article (PubMed ID: 24938388)
1. Posaconazole responsive cerebral aspergillosis in an immunocompetent adult.
Ellenbogen JR; Waqar M; Denning DW; Cooke RP; Skinner DW; Lesser T; Javadpour M
J Clin Neurosci; 2014 Oct; 21(10):1825-7. PubMed ID: 24938388
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole as mono-therapy in orbitofrontal erosive aspergillosis without gross total resection: A case report and review of literature.
Nowak S; Bollmann T; Rosenstengel C; Rathmann E; Ribback S; Ewert R; Schroeder HWS
Clin Neurol Neurosurg; 2018 Sep; 172():93-95. PubMed ID: 29986203
[TBL] [Abstract][Full Text] [Related]
3. [A case of resistant pulmonary and cerebral aspergillosis successfully treated with voriconazole].
Uçan ES; Avkan Oğuz V; Güngör O; Gülşen A; Uğural Sezak N; Tertemiz KC; Ceylan E; Kargi A; Balci P; Ada E; Sanli A
Tuberk Toraks; 2006; 54(1):75-9. PubMed ID: 16615023
[TBL] [Abstract][Full Text] [Related]
4. [Cerebral aspergilloma in an immunocompetent patient: radiological and histopathological findings].
Jiménez Caballero PE; Mollejo Villanueva M
Neurologia; 2009 May; 24(4):275. PubMed ID: 19950422
[No Abstract] [Full Text] [Related]
5. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R; Langston A; Louie A; Ribaud P; Segal BH; Stevens DA; van Burik JA; White CS; Corcoran G; Gogate J; Krishna G; Pedicone L; Hardalo C; Perfect JR
Clin Infect Dis; 2007 Jan; 44(1):2-12. PubMed ID: 17143808
[TBL] [Abstract][Full Text] [Related]
6. Invasive aspergillosis with central nervous system dissemination in a presumably immunocompetent, non-neutropenic patient: case report and review.
Garcia RJ; Troya P; Edwards C
South Med J; 2006 Jun; 99(6):607-10. PubMed ID: 16800416
[TBL] [Abstract][Full Text] [Related]
7. Invasive Aspergillosis: Epidemiology, Clinical Aspects, and Treatment.
Gregg KS; Kauffman CA
Semin Respir Crit Care Med; 2015 Oct; 36(5):662-72. PubMed ID: 26398533
[TBL] [Abstract][Full Text] [Related]
8. Treatment of refractory cerebral aspergillosis in a liver transplant recipient with voriconazole: case report and review of the literature.
Cherian T; Giakoustidis A; Yokoyama S; Heneghan M; O'Grady J; Rela M; Wendon J; Heaton DN; Verma A
Exp Clin Transplant; 2012 Oct; 10(5):482-6. PubMed ID: 23031086
[TBL] [Abstract][Full Text] [Related]
9. Adrenal and hepatic aspergillosis in an immunocompetent patient.
Chen L; Liu Y; Wang W; Liu K
Infect Dis (Lond); 2015 Jun; 47(6):428-32. PubMed ID: 25692352
[TBL] [Abstract][Full Text] [Related]
10. Oral voriconazole for invasive fungal skull base infection.
Parsonage MJ; Stafford ND; Lillie P; Moss PJ; Barlow G; Thaker H
J Laryngol Otol; 2010 Sep; 124(9):1010-3. PubMed ID: 20028605
[TBL] [Abstract][Full Text] [Related]
11. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP
Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405
[TBL] [Abstract][Full Text] [Related]
12. Isolated cerebral aspergillosis in immunocompetent patients.
Bokhari R; Baeesa S; Al-Maghrabi J; Madani T
World Neurosurg; 2014; 82(1-2):e325-33. PubMed ID: 24076053
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
Mouas H; Lutsar I; Dupont B; Fain O; Herbrecht R; Lescure FX; Lortholary O;
Clin Infect Dis; 2005 Apr; 40(8):1141-7. PubMed ID: 15791514
[TBL] [Abstract][Full Text] [Related]
14. [Painful peripheral neuropathy associated with voriconazole during the treatment of chronic cavitary pulmonary aspergillosis].
Gendrot A; de La Blanchardière A; de La Gastine B; Fromager G; Massias L; Verdon R
Rev Med Interne; 2010 Feb; 31(2):163-6. PubMed ID: 19457596
[TBL] [Abstract][Full Text] [Related]
15. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
[TBL] [Abstract][Full Text] [Related]
16. Invasive aspergillosis of orbit in immunocompetent patients: treatment and outcome.
Pushker N; Meel R; Kashyap S; Bajaj MS; Sen S
Ophthalmology; 2011 Sep; 118(9):1886-91. PubMed ID: 21665281
[TBL] [Abstract][Full Text] [Related]
17. Isolated cerebral aspergilloma in a young immunocompetent patient.
Narayan SK; Kumar K; Swaminathan RP; Roopeshkumar VR; Bhavna B
Pract Neurol; 2009 Jun; 9(3):166-8. PubMed ID: 19448060
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
Imai JK; Singh G; Clemons KV; Stevens DA
Antimicrob Agents Chemother; 2004 Oct; 48(10):4063-6. PubMed ID: 15388482
[TBL] [Abstract][Full Text] [Related]
19. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole.
Kuipers S; Brüggemann RJ; de Sévaux RG; Heesakkers JP; Melchers WJ; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2011 Jul; 55(7):3564-6. PubMed ID: 21502625
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole.
Craiglow B; Hinds G; Antaya R; Girardi M
Pediatr Dermatol; 2009; 26(4):493-5. PubMed ID: 19689543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
